Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a severe, chronic, multi-
system neuroimmune disease affecting an estimated 0.89% to 2.5% of the global population.
Characterized by profound post-exertional malaise, unrefreshing sleep, cognitive dysfunction,
and autonomic dysregulation, ME/CFS represents one of the most disabling chronic conditions
in modern medicine. Despite affecting millions worldwide, the disease has historically suffered
from underfunding, dismissal by medical professionals, and classification as a syndrome
rather than a disease with identifiable pathophysiology.

The February 2024 NIH deep phenotyping study fundamentally transformed this landscape
by demonstrating specific biological abnormalities: decreased brain activity in effort-related
neural circuits, exhausted T-cell populations, chronic B-cell activation deficits, and depleted
catecholamine levels in cerebrospinal fluid. These findings conclusively established ME/
CFS as a systemic biological disease with measurable immune, neurological, and metabolic
dysfunction.

This comprehensive documentation synthesizes current research across clinical presentation,
pathophysiological mechanisms, treatment approaches, research evidence, and quantitative
modeling. The work integrates findings from hundreds of peer-reviewed sources spanning
energy metabolism dysfunction, immune exhaustion, neuroinflammation, endocrine dysregu-
lation, cardiovascular abnormalities, gut-brain axis disruption, and genetic-epigenetic factors.
Part I (Chapters 1–5) provides detailed clinical characterization of core and additional
symptoms, the evolution of diagnostic criteria from Fukuda through the Canadian Consen-
sus and International Consensus Criteria, and disease course variations from mild to very
severe presentations including severity-specific phenotyping. Part II (Chapters 6–16) examines
established and hypothetical pathophysiological mechanisms across eleven chapters covering
mitochondrial dysfunction, immune exhaustion, neuroinflammation, endocrine dysregula-
tion, cardiovascular and autonomic failure, gut-microbiome disruption, genetic and epigenetic
factors, integrative multi-system models, speculative mechanistic hypotheses with falsifiable
predictions, symptom-producing mechanisms, and a capstone causal hierarchy analysis classi-
fying all mechanisms as trigger-capable root causes, amplifiers, or downstream consequences.
Part III (Chapters 14a–19) opens with urgent action protocols for severe and very severe cases,
followed by pediatric-specific management for both housebound and ambulatory children,
then documents symptom-based management, medications targeting underlying mechanisms,
supplement regimens, lifestyle interventions, emerging therapies, and integrative personal-
ized approaches. Part IV (Chapters 20–25b) synthesizes biomarker research, clinical trial
outcomes, mechanistic studies, epidemiological patterns, research controversies, translational
findings, research infrastructure proposals, and a set of fully specified proposed studies with
explicit hypotheses and trial designs. Part V (Chapters 26–33) develops formal mathematical
models of disease dynamics using ordinary differential equation systems, presenting energy
metabolism models, immune system dynamics, neuroendocrine and autonomic regulation, integrated multi-system coupling, temporal evolution with tipping-point dynamics, predictive clinical applications for pacing optimization and treatment selection, and a formal causal hierarchy analysis (Chapter 33) that subjects the root cause–amplifier–consequence classification to mathematical testing using sensitivity analysis, bifurcation theory, and the separatrix nudging framework.

Nine appendices provide reference material: a glossary of medical and scientific terms, abbre-
viations, diagnostic tools and assessment scales, patient resources, mathematical derivations
supporting Part V, supplement protocols, a research synthesis, an annotated bibliography of
landmark studies, and a registry of ongoing and planned ME/CFS studies.

Methodologically, this work uses a structured epistemic classification system distinguishing
achievements (high-certainty findings from replicated studies), hypotheses (certainty ≥ 0.45,
requiring validation), speculations (certainty < 0.45, exploratory), predictions (testable claims
for future research), warnings (critical limitations and contraindications), and recommenda-
tions (evidence-based guidance requiring physician review). Evidence quality is systematically
classified as high, medium, or low certainty based on sample size, peer-review status, repli-
cation, and methodological rigor. A cross-document hypothesis registry tracks all speculative
content with falsifiability assessments.

This documentation serves multiple audiences: researchers seeking comprehensive mechanis-
tic understanding and quantitative modeling frameworks, clinicians requiring evidence-based
treatment protocols with dosing guidance and contraindication awareness, patients and
caregivers needing accessible explanations of symptoms and management strategies, and
advocates working toward recognition, funding, and medical education reform. The work
is released under the Creative Commons Attribution 4.0 International License to maximize
accessibility and enable derivative works.

Written by a software architect and researcher with degrees in industrial engineering and man-
agement sciences, this documentation applies systems thinking, computational analysis, and
first-principles reasoning to ME/CFS pathophysiology while maintaining epistemic humility
about the substantial uncertainties remaining in the field. The author explicitly disclaims
medical expertise and emphasizes that all content represents literature synthesis and personal
experience documentation, not clinical advice. All treatment decisions must be made in
consultation with qualified healthcare providers.

ME/CFS research is at a critical inflection point. The biological validation provided by recent
NIH and international studies, combined with shared research agendas driven by Long
COVID parallels, offers unprecedented opportunity for mechanistic discovery and therapeutic
development. This document aims to accelerate progress by organizing scattered findings into
an accessible, comprehensive reference while identifying critical knowledge gaps requiring
focused investigation.